Skip to main content

Advertisement

Table 2 Cost estimates and AE incidences

From: Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China

  Unit cost (US$) Recommended dosage/frequency Cost per month (30 days)
Drug therapy costs
 Sorafenib 1888 (60a 200 mg) 400 mg twice per day 3777
 FOLFOX4   ≈ 2.14 treatment cycles per month 1865
  Oxaliplatin 290 (50 mg) 138 mg per cycle 1716
  5 FU 8 (400 mg) 3247 mg per cycle 132
  LV 16 (1225 mg) 649 mg per cycle 18
  1. aOnly the hospitalization bed fee was counted, as other medical costs during hospitalization have been considered in the model
  2. bTests included abdominal ultrasound, MRI, hematological examination, and liver and kidney function. The tests with similar frequency for the two therapies were not included, e.g., TC tests with costs of US$ 310, which were performed once bi-monthly for each therapy
  Unit cost (US$) Incidence
Sorafenib FOLFOX4
Other medical costs
 General warda 8/day / 5 days per cycle
 Testsb 155/set Once per month Once per cycle
 Adverse event Cost/event   
  Nausea + vomiting 65 11.4% 41.0%
 Abnormal
  AST/ALT values 59 0.0% 31.7%
  Alopecia 0 24.8% 0.0%
  Anorexia 26 12.8% 26.8%
  Bilirubin 349 0.0% 20.2%
  Fatigue 3 20.1% 17.5%
  Diarrhea 13 25.5% 15.9%
  Sensory neuropathy 3 0.0% 15.3%
  HFSR 4 45.0% 0.0%
  Rash 7 20.1% 0.0%
  Hypertension 37 18.8% 0.0%
  Bone marrow suppression 79 0.0% 68.9%
  1. aOnly the hospitalization bed fee was counted, as other medical costs during hospitalization have been considered in the model
  2. bTests included abdominal ultrasound, MRI, hematological examination, and liver and kidney function. The tests with similar frequency for the two therapies were not included, e.g., TC tests with costs of US$ 310, which were performed once bi-monthly for each therapy